Stock LTRN LANTERN PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
6.33 USD +2.26% Intraday chart for Lantern Pharma Inc. -2.31% +47.90%
05-09 Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024
05-09 Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lantern Pharma : Corporate Overview
PU
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
BU
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
BU
Lantern Pharma to Report First Quarter 2024 Operating and Financial Results on May 9th, 2024 at 4:30 p.m. ET
AQ
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
BU
Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists and Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
AQ
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
BU
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
AQ
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
BU
Lantern Pharma : Corporate Overview
PU
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
BU
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
BU
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
BU
Lantern to Participate in H.C Wainwright and Co.'s 1st Annual Artificial Intelligence Based Drug Discovery and Development Virtual Conference
AQ
Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points, Anticipates Reaching 100 Billion Data Points in 2024, paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
AQ
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
BU
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
BU
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
BU
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS and Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
AQ
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LTRN Stock
  4. News Lantern Pharma Inc.
  5. Press Releases